Press Releases

– Conference Call Today at 4:30 p.m. ET – SEATTLE --(BUSINESS WIRE)--Nov. 9, 2022-- Omeros Corporation (Nasdaq: OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan

-- Decision Denies Omeros’ Appeal Requesting Immediate Labeling Discussions -- -- Decision Proposes a Path Forward Based on Historical Survival Data -- SEATTLE --(BUSINESS WIRE)--Nov. 8, 2022-- Omeros Corporation (Nasdaq: OMER) today announced that the Office of New Drugs (OND) of the U.S.

SEATTLE --(BUSINESS WIRE)--Nov. 4, 2022-- Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its third quarter financial results for the period ended September 30, 2022 , on Wednesday, November 9, 2022 , after the market closes.

SEATTLE --(BUSINESS WIRE)--Nov. 3, 2022-- Omeros Corporation (Nasdaq: OMER) today announced that two presentations pertaining to Omeros’ investigational complement inhibitors will be featured at the upcoming 64th American Society of Hematology (ASH) Annual Meeting, which will be held from December

-- Omeros receives $125 million in gross proceeds in sale of a portion of projected royalties receivable on net sales of OMIDRIA – SEATTLE --(BUSINESS WIRE)--Oct. 3, 2022-- Omeros Corporation (Nasdaq: OMER) today announced that Omeros has sold to DRI Healthcare Acquisitions LP (“DRI”), a wholly

-- Reduction in Mortality Risk with Narsoplimab -- SEATTLE --(BUSINESS WIRE)--Sep. 15, 2022-- Omeros Corporation (Nasdaq: OMER) today reported results from the narsoplimab arm of the I-SPY COVID Trial, sponsored by Quantum Leap Healthcare Collaborative (QLHC).

SAN FRANCISCO & SEATTLE --(BUSINESS WIRE)--Sep. 15, 2022-- Quantum Leap Healthcare Collaborative (QLHC), sponsor of the I-SPY COVID Trial, and Omeros Corporation (NASDAQ: OMER), developer of the investigational agent narsoplimab, announced that enrollment has been closed and data have been analyzed

SEATTLE --(BUSINESS WIRE)--Aug. 17, 2022-- Omeros Corporation (Nasdaq: OMER) today announced that the United States Food and Drug Administration (FDA) provided an interim response to the company’s formal dispute resolution request submitted to the Agency in June, appealing the earlier decision by

– Conference Call Today at 4:30 p.m. ET – SEATTLE --(BUSINESS WIRE)--Aug. 9, 2022-- Omeros Corporation (Nasdaq: OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan

SEATTLE --(BUSINESS WIRE)--Aug. 4, 2022-- Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its second quarter financial results for the period ended June 30, 2022 , on Tuesday, August 9, 2022 , after the market closes. Omeros management will host a conference call and

- - Enrollment of PNH Patients Expected to Begin this Summer -- SEATTLE --(BUSINESS WIRE)--Jul. 29, 2022-- Omeros Corporation today announced that OMS906 has received orphan drug designation from the U.S. Food and Drug Administration (FDA) for the treatment of paroxysmal nocturnal hemoglobinuria

SEATTLE --(BUSINESS WIRE)--Jun. 15, 2022-- Omeros Corporation (Nasdaq: OMER), today announced that the company will host a live webcast of its Annual Meeting of Shareholders, which will be held virtually, on Friday, June 17, 2022 , starting at 10:00 a.m. Pacific Time .

– Conference Call Today at 4:30 p.m. ET – SEATTLE --(BUSINESS WIRE)--May 10, 2022-- Omeros Corporation (Nasdaq: OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan

SEATTLE --(BUSINESS WIRE)--May 4, 2022-- Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its first quarter financial results for the period ended March 31, 2022 , on Tuesday, May 10, 2022 , after the market closes. Omeros management will host a conference call and

SEATTLE --(BUSINESS WIRE)--Apr. 20, 2022-- Omeros Corporation (Nasdaq: OMER) today announced the online publication of a manuscript detailing the results of its pivotal study assessing efficacy and safety of narsoplimab for the treatment of hematopoietic stem cell transplant-associated thrombotic

– Conference Call Today at 4:30 p.m. ET – SEATTLE --(BUSINESS WIRE)--Mar. 1, 2022-- Omeros Corporation (Nasdaq: OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan

SEATTLE --(BUSINESS WIRE)--Feb. 24, 2022-- Omeros Corporation (NASDAQ: OMER) today announced that the company will issue its fourth quarter and year-end financial results for the period ended December 31, 2021 , on Tuesday, March 1, 2022 , after the market closes.

SEATTLE --(BUSINESS WIRE)--Jan. 19, 2022-- Omeros Corporation (Nasdaq: OMER) today confirmed that earlier this month the company submitted to the U.S. Food and Drug Administration (FDA) its response to the Agency’s Complete Response Letter (CRL) for narsoplimab in the treatment of hematopoietic